Simple Summary Targeted therapies in children with hematological malignancies moderate
the effects of cytotoxic therapy, thus improving survival rates. They have emerged over the …

Background In the last decade, the use of imatinib has brought a paradigm shift in the
management of chronic myeloid leukemia (CML). In India, imatinib has been available for …

A total of 156 patients (age range 1.3–18.0 years, median 13.2 years; 91 (58.3%) male) with
newly diagnosed CML (N= 146 chronic phase (CML-CP), N= 3 accelerated phase (CML …

Tyrosine Kinase Inhibitors (TKIs) is revolutionizing the management of pediatric Chronic
Myeloid Leukemia (CML), offering alternatives to Allogeneic Hematopoietic Stem Cell …

Background Imatinib, a potent inhibitor of targeted protein tyrosine kinases, treats chronic
myeloid leukaemia (CML). Data on imatinib-associated changes in hepatic and thyroid …

Introduction: The Sokal and Hasford (Euro) scores were developed in the chemotherapy and
interferon eras and are widely used as prognostic indicators in patients with chronic myeloid …

Introduction Chronic myeloid leukemia (CML) is an uncommon malignancy in children in
which tyrosine kinase inhibitors (TKIs) have significantly improved outcome in recent years …

Аннотация Хронический миелоидный лейкоз (ХМЛ) у детей младше 18 лет
встречается редко, в связи с этим нет четких критериев мониторинга и …

Objective: Chronic myeloid leukemia (CML) is relatively rare malignancy in childhood. There
are limited studies of use of Imatinib Mesylate (IM) alone in management of CML in this age …

Background Proper tissue repair and healing after oral surgery are vital to achieve optimal
outcomes. Certain medications may interfere with wound healing, but this debilitating …